Under the terms of the agreement, Keata will retain the facility’s approximately 175 employees operating the 85,000 sq ft facility. Concurrently, Keata will enter into supply agreements with Pfizer for the exclusive manufacture of certain Pfizer products for Canada at the Arnprior facility for a period of three years.
Keata will also manufacture products from the Arnprior location for two other major pharmaceutical clients with multi year supply contracts, becoming a world wide supplier to more than 30 countries.
Alan Kwong, CEO of PharmEng, said: “Along with the recently opened new facility in Nova Scotia, this acquisition allows Keata flexibility with our manufacturing capabilities and improves cost effectiveness throughout our manufacturing operations.”